Balyasny Asset Management
AQST icon

Balyasny Asset Management’s Aquestive Therapeutics AQST Stock Holding History

Balyasny Asset Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-500,000
Closed -$2.79M – 3061
2025
Q3 		$2.79M Buy
+500,000
New +$2.16M ﹤0.01% 1649

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Balyasny Asset Management's AQST Position: Q1 2026 in Review

Balyasny Asset Management increased its Aquestive Therapeutics (AQST) stake by 199% in Q1 2026, buying an estimated $7.83M and bringing the position to 2,900,570 shares worth $12M. The position accounts for 0.02% of the portfolio, ranked #953.

Balyasny Asset Management first reported a position in AQST in Q3 2021 and has held it in 4 quarters since. 180 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Balyasny Asset Management held 2,900,570 shares of Aquestive Therapeutics worth $12M as of Q1 2026.
  • Balyasny Asset Management bought 1,929,631 Aquestive Therapeutics shares in Q1 2026, an estimated $7.83M.
  • Aquestive Therapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q1 2026, its #953 holding.
  • Balyasny Asset Management first reported a position in Aquestive Therapeutics in Q3 2021 and has held it in 4 quarters since.
  • 180 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.